COMPPARE Enrolls 750 Patients

On the road with COMPPAREThe COMPPARE team was pleased to announce in August that the study had enrolled 750 patients, 25% of its 3,000-patient goal.

COMPPARE stands for “A Prospective COMparative Study of Outcomes with Proton and Photon RAdiation in PRostate CancEr (COMPPARE).” The study compares the quality of life, side effects, and cure rates for prostate cancer patients treated with proton therapy or photon therapy. Participants answer brief surveys regarding treatment choice, quality of life, and side effects for at least 3 years. In addition, proton therapy patients can choose to participate in a randomized trial that will evaluate whether quality of life, side effects, and prostate cancer cure rates differ between patients receiving the standard therapy versus a shorter therapy.

The study will enroll 1500 patients receiving photon therapy and 1500 patients receiving proton therapy. As of September 18, 2020, COMPPARE had enrolled 855 participants, comprising 171 photon participants, 213 Randomized Control Trial (RCT) proton participants, and 471 pragmatic proton participants.

Prostate cancer patients are participating in COMPPARE from across the US, including many enrolled through partner sites in Florida, California, Texas, and Minnesota (The MD Anderson COMPPARE research team with Dr. Nancy Mendenhall and Charles Griggs, shown above).

Thank you to our patients who make this study possible!